SCHEMBL19654203

SCHEMBL19654203

CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2C)ncc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 7/20 0.60
▸ PKMYT1 Q99640 2/20 0.58
▸ ULK1 O75385 4/20 0.56
▸ MAPK3 P27361 2/20 0.55
▸ AXL P30530 1/20 0.54
▸ MERTK Q12866 1/20 0.54
▸ AURKA O14965 2/20 0.50
▸ FGFR1 P11362 2/20 0.50
▸ FGFR3 P22607 2/20 0.50
▸ FGFR2 P21802 1/20 0.50
▸ FGFR4 P22455 1/20 0.50
▸ MAPK10 P53779 3/20 0.49
▸ MAPK8 P45983 2/20 0.49
▸ MAPK9 P45984 2/20 0.49
▸ CDC7 O00311 1/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ CHEK1 O14757 1/20 0.49
▸ DCLK1 O15075 1/20 0.49
▸ PDPK1 O15530 1/20 0.49
▸ DAPK3 O43293 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17547457 0.91 ULK1 (0.64) PTK2PKMYT1ULK1MAPK3AXL
SCHEMBL17547462 0.91 ULK1 (0.70) PTK2ULK1MAPK3AURKAFGFR1
SCHEMBL17547550 0.89 MAPK3 (0.71) PTK2ULK1MAPK3CDC7JAK2
SCHEMBL19654252 0.83 ULK1 (0.55) PTK2ULK1MAPK3AXLMERTK
SCHEMBL19654274 0.82 PTK2 (0.50) PTK2ULK1MAPK3AXLMERTK
SCHEMBL12879897 0.81 PKMYT1 (0.63) PTK2PKMYT1ULK1AURKAMAPK10
SCHEMBL23754823 0.81 PTK2 (0.73) PTK2PKMYT1ULK1AXLFGFR1
SCHEMBL19654199 0.80 ULK1 (0.68) PTK2PKMYT1ULK1AXLFGFR1
SCHEMBL17544443 0.79 ULK1 (0.67) PTK2ULK1MAPK3AXLMERTK
SCHEMBL19654253 0.78 PTK2 (0.61) PTK2ULK1AXLMERTKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 PTK2 884/4885PKMYT1 1670/4885ULK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback